Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 172 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clostridium Difficile Infection Clear all
Terminated Phase 2 Interventional Results available

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

NCT02053350
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Alanyl-glutamine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of a Single Dose of CRS3123

NCT01551004
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
CRS3123, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 1, 2026, 1:55 AM EDT
Withdrawn No phase listed Observational

Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)

NCT04070352
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
Fidaxomicin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 1, 2026, 1:55 AM EDT
Completed No phase listed Observational

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

NCT04317963
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Bezlotoxumab, Standard CDI treatment
Biological · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Not listed Phase 4 Interventional

Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection

NCT02237859
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin, fruit juice/placebo
Drug · Dietary Supplement
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

NCT03548051
View directory record Official record
Conditions
Clostridial Infection, Dysbiosis, Probiotic Therapy
Interventions
Fecal Microbiota Transplantation (FMT), Saline
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Decatur, Georgia • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 3 Interventional

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

NCT00466635
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
Interventions
GT267-004 (tolevamer potassium sodium)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Modesto, California • Honolulu, Hawaii • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

NCT02830542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-262, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 2 Interventional Results available

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

NCT03970200
View directory record Official record
Conditions
Severe Clostridium Difficile Infection, Severe-Complicated/Fulminant Clostridium Difficile Infection
Interventions
Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003, Antibiotics
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Not applicable Interventional Results available

Effect of Acid Suppression Medication on Pediatric Microbiome

NCT02016820
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Omeprazole (suspension), Lifestyle Modification
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
0 Years to 4 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

NCT00130221
View directory record Official record
Conditions
Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions
2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap
Drug · Other
Lead sponsor
Cook County Health
Government
Eligibility
16 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

NCT02200328
View directory record Official record
Conditions
Clostridium Difficile Diarrhea
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Alison Schneider
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

NCT02437487
View directory record Official record
Conditions
Clostridium Difficile
Interventions
SER-109, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Oceanside, California • Sacramento, California • Ventura, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT03030248
View directory record Official record
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed No phase listed Observational

REBYOTA™ Prospective Registry

NCT05835219
View directory record Official record
Conditions
Recurrence of Clostridium Difficile Infection
Interventions
REBYOTA™
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Chandler, Arizona • Chula Vista, California • Murrieta, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation

NCT03621657
View directory record Official record
Conditions
Clostridium Difficile Infection, C.Difficile Diarrhea, CDI
Interventions
Low Dose FMT Capsule DE, Single Dose FMT Capsule DE, Placebo oral capsule
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

NCT05153499
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
CP101, Placebo
Biological · Other
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
61
States / cities
Phoenix, Arizona • Mission Hills, California • Oakland, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Not listed Phase 1 Interventional

Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection

NCT02134392
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Jonathan Gisser
Other
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 1, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

NCT07513285
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Ibezapolstat
Drug
Lead sponsor
Acurx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Sacramento, California • Hamden, Connecticut • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

NCT02563106
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Infections
Interventions
SYN-004, Placebo
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Little Rock, Arkansas • Torrance, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 2 Interventional Results available

Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

NCT03298048
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
Low fecal microbiota dose, Mid fecal microbiota dose, High fecal microbiota dose
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

NCT03931941
View directory record Official record
Conditions
Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions
RBX2660
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 1, 2026, 1:55 AM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

NCT03617172
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Misoprostol 100Mcg Tab, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 1, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

NCT04781387
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
CRS3123, Active Comparator
Drug
Lead sponsor
Crestone, Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Fullerton, California • Lancaster, California • Mission Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 1, 2026, 1:55 AM EDT